USPTO serial 98525292
SMB
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- NOVAKOVIC, MIROSLAV
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with SMB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Miryang-si, KR
Miryang-si, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jihun Kim
Jihun Kim Bridgeway IP Law Group, PLLC11350 Random Hills RdSuite 800Fairfax, VA 22030Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; vitamins and mineral supplements; crude medicines for the treatment of gastrointestinal diseases; crude medicines, namely, medicinal preparations for use in dermatology; crude medicines, namely, plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; crude medicines, namely, medicines for treating neurological disease, muscular disease, ischemic disease, renal disease, and cancer; antibacterial pharmaceuticals; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for the treatment of infectious diseases; diagnostic radiopharmaceutical preparations; pharmaceutical drugs for the treatment of metabolic disorders, namely, obesity, comorbidities secondary to obesity, metabolic syndrome, and related metabolic diseases; pharmaceutical drugs for the treatment of joint disorders and osteoarthritis; cough pastilles for pharmaceutical purposes; lotions for pharmaceutical purposes, namely, medicated skin lotions, medicated hair lotions, medicated sunburn lotions, calamine lotion, medicated after-shave lotions, collyrium, anti-bacterial hand lotions; chemical preparations for pharmaceutical use, namely, for the treatment of neurodegenerative disorders, neurological conditions, cancer, skin conditions, or for use in wound healing or photodynamic therapy; chemical preparations for pharmaceutical use, namely, for the treatment of fungal, viral, bacterial and infectious diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 11, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 11, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 10, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 10, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 10, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 28, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 28, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 28, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 28, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 11, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 17, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 17, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 11, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 20, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 20, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 20, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 20, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 20, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 14, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 29, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 29, 2024 | NWAP | NEW APPLICATION ENTERED | — |